

AS AT AUGUST 31, 2019

FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

FUND DETAILS

Inception date	July 1996
Total net assets (\$CAD) As at 2019-08-31	\$181.2 million
NAVPS	\$42.2951
MER (%) As at 2018-09-30	2.42
Management fee (%)	1.900
Asset class	Industry-Specific
Currency	CAD
Minimum investment	\$500 initial / \$25 additional
Distribution frequency	Quarterly
Last distribution	\$0.9043

Risk rating³



FUND CODES


A	ISC 201 DSC 701 LL 1701
E	16005
EF	15005
F	224
I	886
O	18005
P	90024
Y	4924
Z	ISC 2924 DSC 2925 LL 2928

DISTRIBUTION HISTORY⁴


Payable date	Total	Payable date	Total
2019-06-21	0.5646	2018-03-23	0.9725
2019-03-22	0.9043	2017-03-31	0.3744
2018-12-14	0.1415	2016-03-24	2.3925
2018-09-14	0.1401	2015-03-27	3.0075
2018-06-22	0.1401	2014-03-28	0.7025

PERFORMANCE¹

Growth of \$10,000 (since inception date)



Calendar year performance



Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
-5.3%	-4.9%	-7.2%	-11.8%	-18.8%	-2.6%	-0.1%	10.2%	7.9%

*Since inception date

PORTFOLIO ALLOCATIONS²

Asset allocation	(%)	Sector allocation	(%)
US Equity	60.08%	Healthcare	83.79%
International Equity	35.45%	Consumer Services	10.55%
Cash and Equivalents	3.20%	Cash and Cash Equivalent	3.20%
Canadian Equity	1.23%	Real Estate	2.42%
Other	0.04%	Other	0.04%

Geographic allocation	(%)
United States	61.61%
Japan	12.50%
Germany	6.31%
United Kingdom	5.49%
Switzerland	4.02%
France	3.15%
Canada	2.90%
Other	1.42%
Singapore	1.41%
Brazil	1.19%

AS AT AUGUST 31, 2019

TOP HOLDINGS

	Sector	(%)
1. SeaSpine Holdings Corp	Diversified Healthcare	5.06%
2. Intercept Pharmaceuticals Inc	Drugs	4.89%
3. Biogen Idec Inc	Drugs	4.84%
4. Alexion Pharmaceuticals Inc	Drugs	4.81%
5. Bristol-Myers Squibb Co	Drugs	4.77%
6. Takeda Pharmaceutical Co Ltd	Drugs	4.73%
7. CVS Health Corp	Retail	4.48%
8. Astellas Pharma Inc	Drugs	4.38%
9. Roche Holding AG - Participation	Diversified Healthcare	4.02%
10. GlaxoSmithKline PLC	Drugs	3.82%
11. Merit Medical Systems Inc	Drugs	3.81%
12. Fresenius Medical Care AG & Co KGaA	Healthcare Services	3.46%
13. Sugi Holdings Co Ltd	Retail	3.39%
14. Sangamo BioSciences Inc	Diversified Healthcare	3.34%
15. Sanofi SA	Drugs	3.15%

MANAGEMENT TEAM



Altrinsic Global Advisors follows a fundamental value approach to seek out high-quality undervalued companies worldwide. Altrinsic was founded by John Hock and associates and a sub-advisor to CI Investments Inc., a subsidiary of CI Financial Corp. CI Financial Corp. holds a minority interest in Altrinsic Global Advisors.



Andrew Waight

Over 35,000 financial advisors have chosen CI Investments as a partner. We believe that Canadians have the best opportunity for investment success by using the services of a professional financial advisor. [Learn more at ci.com](http://ci.com).

¹ Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns (net of fees and expenses payable by the fund) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

² Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

³ The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

⁴ Please refer to the fund's simplified prospectus for distribution information.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

© CI Investments and the CI Investments design are registered trademarks of CI Investments Inc. © CI Investments Inc. 2019. All rights reserved. 2019. "Trusted Partner in Wealth™" is a trademark of CI Investments Inc.

Published August 2019